THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.9] ID: TIP-MED-000213

Levetiracetam

Active Ingredient / Scientific Identity: Levetiracetam • Class: Second-Generation Pyrrolidone Antiepileptic (Binds Synaptic Vesicle Protein 2A [SV2A] to Modulate Neurotransmitter Release)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Levetiracetam ([11.9] | ID: TIP-MED-000213) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-9-levetiracetam/
Generic / Entity NameLevetiracetam ([11.9])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSecond-Generation Pyrrolidone Antiepileptic (Binds Synaptic Vesicle Protein 2A [SV2A] to M
Available Dosage FormsOral Film-Coated Tablets: 250 mg, 500 mg, 750 mg, 1000 mg; Extended-Release (XR) Tablets: 500 mg, 750 mg, 1000
Regulatory ClassificationSchedule H Prescription Drug • NLEM 2022 Core Essential Medicine
Key Warning & Review DateNo adjustment required in mild-to-moderate hepatic impairment (no CYP450 metabolism).
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • NLEM 2022 Core Essent✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Levetiracetam (TIP-MED-000213, Reference Code [11.9]) is classified under Neurology & Antiepileptic Medicines (Ch 11) as a Second-Generation Pyrrolidone Antiepileptic (Binds Synaptic Vesicle Protein 2A [SV2A] to Modulate Neurotransmitter Release). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.9], p. 144): Keppra (UCB/Dr. Reddy's), Levera (Intas), Levipil (Sun Pharma), Epifast, Torleva (Torrent); Extended-Release: Levera-XR, Levipil-XR (500 mg, 750 mg, 1000 mg) — Strengths & Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg, 1000 mg; Extended-Release (XR) Tablets: 500 mg, 750 mg, 1000 mg; Oral Solution: 100 mg/mL; IV Injection: 500 mg/5 mL (100 mg/mL)
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.9], p. 144): Keppra (UCB/Dr. Reddy's), Levera (Intas), Levipil (Sun Pharma), Epifast, Torleva (Torrent); Extended-Release: Levera-XR, Levipil-XR (500 mg, 750 mg, 1000 mg) — Strengths & Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg, 1000 mg; Extended-Release (XR) Tablets: 500 mg, 750 mg, 1000 mg; Oral Solution: 100 mg/mL; IV Injection: 500 mg/5 mL (100 mg/mL)
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg, 1000 mg; Extended-Release (XR) Tablets: 500 mg, 750 mg, 1000 mg; Oral Solution: 100 mg/mL; IV Injection: 500 mg/5 mL (100 mg/mL)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Binds selectively to Synaptic Vesicle Glycoprotein 2A (SV2A) on presynaptic neurotransmitter vesicles in the brain, modulating Ca2+-dependent synaptic vesicle fusion and limiting excessive glutamate release during high-frequency epileptiform bursts without altering normal voltage-gated Na+ or GABAergic currents.

4. Therapeutic Indications & Evidence-Supported Uses

  • Focal-onset seizures (with or without secondary generalization) as monotherapy or adjunctive therapy
  • Juvenile Myoclonic Epilepsy (myoclonic seizures) and Primary Generalized Tonic-Clonic seizures
  • Benzodiazepine-refractory Status Epilepticus (second-line IV loading alongside Phenytoin/Valproate — ESETT trial)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults: Start 500 mg orally or IV twice daily; titrate by 500 mg BD every 2 weeks to 1000–1500 mg twice daily (max 3000 mg/day). Status Epilepticus IV Load: 60 mg/kg (max 4500 mg) over 15 minutes.

Administration & Meal Timing: Oral or Intravenous (1:1 bioequivalent oral-to-IV conversion).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
No adjustment required in mild-to-moderate hepatic impairment (no CYP450 metabolism).
Elimination & Renal Adjustment:
Mandatory dose adjustment based on CrCl (since 66% excreted unchanged renally): CrCl 50–79 mL/min -> 500–1000 mg q12h; CrCl 30–49 mL/min -> 250–750 mg q12h; CrCl < 30 mL/min -> 250–500 mg q12h.
Hepatic Impairment Considerations:
No adjustment required in mild-to-moderate hepatic impairment (no CYP450 metabolism).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to Levetiracetam or pyrrolidine derivatives

Key Clinical Precautions: No adjustment required in mild-to-moderate hepatic impairment (no CYP450 metabolism).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Neuropsychiatric / behavioural adverse effects ('Keppra rage' — irritability, agitation, mood swings, aggression, depression in 10%–15% of patients; partially mitigated by Pyridoxine B6)
  • Somnolence, asthenia, fatigue, and dizziness
  • Rare SJS/TEN or pancytopenia
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Virtually ZERO pharmacokinetic CYP450 or UGT drug-drug interactions (does not induce or inhibit hepatic enzymes and does not reduce oral contraceptive or Warfarin efficacy)
  • Methotrexate: rare reports of decreased renal Methotrexate clearance

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Take twice daily at 12-hour intervals; never stop antiepileptic therapy abruptly as this can trigger status epilepticus.
  • Report significant irritability, uncharacteristic anger, mood changes, or depression to your neurologist.
  • Safe in women of childbearing potential (much lower teratogenicity than Valproate or Phenytoin) and does not interact with oral contraceptives.

Storage, Stability & Dispensing Safeguards: Store below 30°C.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-9-levetiracetam/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.